|
1
|
Antoni S, Ferlay J, Soerjomataram I, Znaor
A, Jemal A and Bray F: Bladder cancer incidence and mortality: A
global overview and recent trends. Eur Urol. 71:96–108. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sievert KD, Amend B, Nagele U, Schilling
D, Bedke J, Horstmann M, Hennenlotter J, Kruck S and Stenzl A:
Economic aspects of bladder cancer: What are the benefits and
costs? World J Urol. 27:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Babjuk M, Oosterlinck W, Sylvester R,
Kaasinen E, Böhle A, Palou-Redorta J and Rouprêt M: European
association of urology (EAU): EAU guidelines on non-muscle-invasive
urothelial carcinoma of the bladder, the 2011 update. Eur Urol.
59:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stenzl A, Cowan NC, De Santis M, Kuczyk
MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: European
association of urology (EAU): Treatment of muscle-invasive and
metastatic bladder cancer: Update of the EAU guidelines. Eur Urol.
59:1009–1018. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wei L, Chintala S, Ciamporcero E,
Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu
L, et al: Genomic profiling is predictive of response to cisplatin
treatment but not to PI3K inhibition in bladder cancer
patient-derived xenografts. Oncotarget. 7:76374–76389. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Glaser AP, Fantini D, Shilatifard A,
Schaeffer EM and Meeks JJ: The evolving genomic landscape of
urothelial carcinoma. Nat Rev Urol. 14:215–229. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choi W, Ochoa A, McConkey DJ, Aine M,
Höglund M, Kim WY, Real FX, Kiltie AE, Milsom I, Dyrskjøt L and
Lerner SP: Genetic alterations in the molecular subtypes of bladder
cancer: Illustration in the cancer genome atlas dataset. Eur Urol.
72:354–365. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malik S and Roeder RG: The metazoan
mediator co-activator complex as an integrative hub for
transcriptional regulation. Nat Rev Genet. 11:761–772. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai G, Imasaki T, Takagi Y and Asturias
FJ: Mediator structural conservation and implications for the
regulation mechanism. Structure. 17:559–567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ansari SA and Morse RH: Mechanisms of
mediator complex action in transcriptional activation. Cell Mol
Life Sci. 70:2743–2756. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boube M, Joulia L, Cribbs DL and Bourbon
HM: Evidence for a mediator of RNA polymerase II transcriptional
regulation conserved from yeast to man. Cell. 110:143–151. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao M, Yang X, Fu Y, Wang H, Ning Y, Yan
J, Chen YG and Wang G: Mediator MED15 modulates transforming growth
factor beta (TGFβ)/Smad signaling and breast cancer cell
metastasis. J Mol Cell Biol. 5:57–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Offermann A, Shaikhibrahim Z and Perner S:
MED15: A potential biomarker for head and neck squamous cell
carcinoma? Biomark Med. 9:939–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Jiang H, Wang W, Gong J, Zhang L,
Chen Z and Ding Q: Expression of Med19 in bladder cancer tissues
and its role on bladder cancer cell growth. Urol Oncol. 30:920–927.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klümper N, Syring I, Vogel W, Schmidt D,
Müller SC, Ellinger J, Shaikhibrahim Z, Brägelmann J and Perner S:
Mediator complex subunit MED1 protein expression Is decreased
during bladder cancer progression. Front Med (Lausanne).
4:302017.PubMed/NCBI
|
|
16
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
19
|
Scheble VJ, Braun M, Wilbertz T, Stiedl
AC, Petersen K, Schilling D, Reischl M, Seitz G, Fend F,
Kristiansen G and Perner S: ERG rearrangement in small cell
prostatic and lung cancer. Histopathology. 56:937–943. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Scheble VJ, Braun M, Beroukhim R, Mermel
CH, Ruiz C, Wilbertz T, Stiedl AC, Petersen K, Reischl M, Kuefer R,
et al: ERG rearrangement is specific to prostate cancer and does
not occur in any other common tumor. Mod Pathol. 23:1061–1067.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Allen BL and Taatjes DJ: The mediator
complex: A central integrator of transcription. Nat Rev Mol Cell
Biol. 16:155–166. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolan WL and Chapple C: Conservation and
divergence of Mediator structure and function: Insights from
plants. Plant Cell Physiol. 58:4–21. 2017.PubMed/NCBI
|
|
23
|
Kosan C and Godmann M: Bringing light into
gene regulation in hematopoietic stem cells by the Mediator
complex. Stem Cell Investig. 4:102017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Caro-Llopis A, Rosello M, Orellana C,
Oltra S, Monfort S, Mayo S and Martinez F: De novo mutations in
genes of Mediator complex causing syndromic intellectual
disability: Mediatorpathy or transcriptomopathy? Pediatr Res.
80:809–815. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schiano C, Casamassimi A, Vietri MT,
Rienzo M and Napoli C: The roles of Mediator complex in
cardiovascular diseases. Biochim Biophys Acta. 1839:444–451. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schiano C, Casamassimi A, Rienzo M, de
Nigris F, Sommese L and Napoli C: Involvement of Mediator complex
in malignancy. Biochim Biophys Acta. 1845:66–83. 2014.PubMed/NCBI
|
|
27
|
Jiang C, Chen H, Shao L and Wang Q:
MicroRNA-1 functions as a potential tumor suppressor in
osteosarcoma by targeting Med1 and Med31. Oncol Rep. 32:1249–1256.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HJ, Roh MS, Son CH, Kim AJ, Jee HJ,
Song N, Kim M, Seo SY, Yoo YH and Yun J: Loss of Med1/TRAP220
promotes the invasion and metastasis of human non-small-cell lung
cancer cells by modulating the expression of metastasis-related
genes. Cancer Lett. 321:195–202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mansouri S, Naghavi-Al-Hosseini F,
Farahmand L and Majidzadeh-A K: MED1 may explain the interaction
between receptor tyrosine kinases and ERα66 in the complicated
network of Tamoxifen resistance. Eur J Pharmacol. 804:78–81. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Y, Meng Q, Gao X, Zhang L and An L:
Down-regulation of Mediator complex subunit 19 (Med19) induces
apoptosis in human laryngocarcinoma HEp2 cells in an
Apaf-1-dependent pathway. Am J Transl Res. 9:755–761.
2017.PubMed/NCBI
|
|
31
|
Offermann A, Vlasic I, Syring I, Vogel W,
Ruiz C, Zellweger T, Rentsch CA, Hagedorn S, Behrends J, Nowak M,
et al: MED15 overexpression in prostate cancer arises during
androgen deprivation therapy via PI3K/mTOR signaling. Oncotarget.
8:7964–7976. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tamarkin FJ, Kang WS, Cohen JJ, Wheeler MA
and Weiss RM: A role for Akt in the rapid regulation of
inflammatory and apoptotic pathways in mouse bladder. Naunyn
Schmiedebergs Arch Pharmacol. 373:349–359. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kiselyov A, Bunimovich-Mendrazitsky S and
Startsev V: Key signaling pathways in the muscle-invasive bladder
carcinoma: Clinical markers for disease modeling and optimized
treatment. Int J Cancer. 138:2562–2569. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li J, Lv B, Li X, He Z and Zhou K:
Apoptosis-related molecular differences for response to tyrosin
kinase inhibitors in drug-sensitive and drug-resistant human
bladder cancer cells. J Cancer Res Ther. 9:668–671. 2013.
View Article : Google Scholar : PubMed/NCBI
|
